AU2001253471B2 - Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof - Google Patents

Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof Download PDF

Info

Publication number
AU2001253471B2
AU2001253471B2 AU2001253471A AU2001253471A AU2001253471B2 AU 2001253471 B2 AU2001253471 B2 AU 2001253471B2 AU 2001253471 A AU2001253471 A AU 2001253471A AU 2001253471 A AU2001253471 A AU 2001253471A AU 2001253471 B2 AU2001253471 B2 AU 2001253471B2
Authority
AU
Australia
Prior art keywords
ribozyme
toxic
pathogen
ribozymes
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001253471A
Other languages
English (en)
Other versions
AU2001253471A1 (en
Inventor
Gary A. Clawson
Joseph Dolan
Brian Hoel
James S. Norris
Weihua Pan
Michael G Schmidt
David Schofield
Caroline Westwater
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical University of South Carolina (MUSC)
Penn State Research Foundation
Original Assignee
Medical University of South Carolina (MUSC)
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical University of South Carolina (MUSC), Penn State Research Foundation filed Critical Medical University of South Carolina (MUSC)
Publication of AU2001253471A1 publication Critical patent/AU2001253471A1/en
Application granted granted Critical
Publication of AU2001253471B2 publication Critical patent/AU2001253471B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
AU2001253471A 2000-04-13 2001-04-13 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof Ceased AU2001253471B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54844900A 2000-04-13 2000-04-13
US09/548,449 2000-04-13
US25181000P 2000-12-07 2000-12-07
US60/251,810 2000-12-07
PCT/US2001/012130 WO2001079524A2 (en) 2000-04-13 2001-04-13 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2001253471A1 AU2001253471A1 (en) 2002-01-17
AU2001253471B2 true AU2001253471B2 (en) 2007-07-26

Family

ID=26941841

Family Applications (2)

Application Number Title Priority Date Filing Date
AU5347101A Pending AU5347101A (en) 2000-04-13 2001-04-13 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof
AU2001253471A Ceased AU2001253471B2 (en) 2000-04-13 2001-04-13 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU5347101A Pending AU5347101A (en) 2000-04-13 2001-04-13 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof

Country Status (5)

Country Link
EP (1) EP1397489A4 (de)
JP (1) JP2004525602A (de)
AU (2) AU5347101A (de)
CA (1) CA2406403A1 (de)
WO (1) WO2001079524A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183011B2 (en) * 2003-06-13 2012-05-22 University Of Medicine And Dentistry Of New Jersey RNA interferases and methods of use thereof
WO2005046579A2 (en) * 2003-10-06 2005-05-26 Gangagen, Inc. Defined dose therapeutic phage
SG10201805660WA (en) 2013-12-30 2018-08-30 Curevac Ag Methods for rna analysis
WO2019171191A1 (en) * 2018-03-05 2019-09-12 Dr. Reddy's Institute Of Life Sciences Embryonic zebrafish models using dnazyme mediated knockdown

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001815A1 (en) * 1990-07-19 1992-02-06 Royal Free Hospital School Of Medicine Method for the diagnosis of human pappiloma virus type 16 using the polymerase chain reaction
WO1993002217A2 (fr) * 1991-07-17 1993-02-04 Clonatec S.A. Sondes oligonucleotidiques pour le typage et la detection des papillomavirus humains

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0502994B1 (de) * 1989-12-01 1995-09-06 Amoco Corporation Detektion von hpv-transkripts
WO1993023569A1 (en) * 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
US5767259A (en) * 1994-12-27 1998-06-16 Naxcor Oligonucleotides containing base-free linking groups with photoactivatable side chains
EP0655091A1 (de) * 1993-05-06 1995-05-31 Baxter Diagnostics Inc. Nachweismethode des menschlichen papillomavirus
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins
US5985662A (en) * 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
AU5298699A (en) * 1998-08-13 2000-03-06 Johnson & Johnson Research Pty. Limited Dnazymes and methods for treating hpv-related disorders
AU2875602A (en) * 2000-12-07 2002-06-18 Univ Pennsylvania Selection of catalytic nucleic acids targeted to infectious agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001815A1 (en) * 1990-07-19 1992-02-06 Royal Free Hospital School Of Medicine Method for the diagnosis of human pappiloma virus type 16 using the polymerase chain reaction
WO1993002217A2 (fr) * 1991-07-17 1993-02-04 Clonatec S.A. Sondes oligonucleotidiques pour le typage et la detection des papillomavirus humains

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Alvarez-Salas et al (1998) PNAS 95: 1189-1194. *

Also Published As

Publication number Publication date
CA2406403A1 (en) 2001-10-25
WO2001079524A2 (en) 2001-10-25
EP1397489A4 (de) 2005-05-11
AU5347101A (en) 2001-10-30
WO2001079524A3 (en) 2004-01-08
EP1397489A2 (de) 2004-03-17
JP2004525602A (ja) 2004-08-26

Similar Documents

Publication Publication Date Title
US20060223774A1 (en) Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof
US6271359B1 (en) Tissue-specific and pathogen-specific toxic agents and ribozymes
US7575918B2 (en) Tissue-specific and pathogen-specific ribozymes
NZ333802A (en) Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
US7732197B2 (en) Tissue-specific and target RNA-specific ribozymes
AU2001253471B2 (en) Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof
AU2001253471A1 (en) Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof
WO2021021636A1 (en) Oligonucleotide antagonists for rna guided genome editing
CA2516425A1 (en) Rna interference compositions and methods
WO1998024925A1 (en) Tissue specific and target rna-specific ribozymes as antimicrobial therapeutics against microbial pathogens
US7439059B2 (en) Compositions and methods for activating genes of interest
EP1702983A2 (de) Gewebespezifische und pathogenspezifische giftige Verbindungen, Ribozyme, DNAzyme und Antisense-Oligonukleotide sowie Anwendungen dafür
US20030032612A1 (en) Oligonucleotides specific for the marORAB operon
AU743119B2 (en) Tissue specific and target RNA-specific ribozymes as antimicrobial therapeutics against microbial pathogens
US20030125280A1 (en) Tissue specific and target RNA-specific ribozymes as antimicrobial therapeutics against microbial pathogens
AU2004201285B2 (en) Tissue-specific and target RNA-specific ribozymes
WO2022248879A1 (en) Composition and method for adar-mediated rna editing

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired